Cencora, Inc. $COR Shares Sold by Coho Partners Ltd.

Coho Partners Ltd. lessened its stake in Cencora, Inc. (NYSE:COR) by 43.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 121,408 shares of the company’s stock after selling 92,180 shares during the period. Cencora accounts for 4.9% of Coho Partners Ltd.’s portfolio, making the stock its 2nd biggest holding. Coho Partners Ltd. owned about 0.06% of Cencora worth $37,944,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Baader Bank Aktiengesellschaft boosted its holdings in shares of Cencora by 318.5% during the second quarter. Baader Bank Aktiengesellschaft now owns 4,336 shares of the company’s stock worth $1,300,000 after purchasing an additional 3,300 shares during the period. Voleon Capital Management LP purchased a new stake in Cencora in the 1st quarter worth approximately $3,111,000. Focus Partners Wealth boosted its stake in shares of Cencora by 25.8% during the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after buying an additional 1,171 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the period. Finally, Martin Capital Partners LLC grew its holdings in shares of Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after acquiring an additional 2,544 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on COR. UBS Group increased their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Evercore ISI set a $400.00 price target on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Robert W. Baird set a $392.00 price objective on Cencora in a report on Tuesday, December 16th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $373.25.

Cencora Stock Performance

COR opened at $339.86 on Tuesday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The company has a market cap of $65.93 billion, a PE ratio of 42.75, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. The stock has a 50-day moving average of $346.94 and a 200-day moving average of $313.70. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $377.54.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.